Cerebrospinal Fluid-Administered Therapies for Leptomeningeal Metastases from Solid Tumors

References

• Chamberlain M , JunckL, BrandsmaDet al. Leptomeningeal metastases: a RANO proposal for response criteria. Neuro Oncol.19(4), 484–492 (2017).
   PubMed Web of Science ®Google Scholar
• Beauchesne P . Intrathecal chemotherapy for treatment of leptomeningeal dissemination of metastatic tumours. Lancet Oncol.11(9), 871–879 (2010).
   PubMed Web of Science ®Google Scholar
• Thakkar JP , KumthekarP, DixitKS, StuppR, LukasRV. Leptomeningeal metastasis from solid tumors. J. Neurol. Sci.411, 116706 (2020).
   PubMed Web of Science ®Google Scholar
• Lukas RV , ThakkarJP, CristofanilliMet al. Leptomeningeal metastases: the future is now. J. Neurooncol.156(3), 443–452 (2022).
   PubMed Web of Science ®Google Scholar
• Cohen SP , DragovichA. Intrathecal analgesia. Anesthesiol. Clin.25(4), 863–882 (2007).
   PubMedGoogle Scholar
• Molander L , CarawayC, LinderbeckL, LaberDA. Cerebrospinal fluid (CSF) directed antineoplastic agents: a review of current knowledge. J. Cancer Prev. Curr. Res.2(2), 26 (2015).
   Google Scholar
• Montes de Oca Delgado M , DiazBC, ZambranoJSet al. The comparative treatment of intraventricular chemotherapy by Ommaya reservoir vs. lumbar puncture in patients with leptomeningeal carcinomatosis. Front. Oncol.8, 509 (2018).
   PubMed Web of Science ®Google Scholar
• Shapiro WR , YoungDF, MehtaBM. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections. N. Engl. J. Med.293(4), 161–166 (1975).
   PubMed Web of Science ®Google Scholar
• Delhaas EM , HuygenF. Complications associated with intrathecal drug delivery systems. BJA Educ.20(2), 51–57 (2020).
   PubMed Web of Science ®Google Scholar
• Byrnes DM , VargasF, DermarkarianCet al. Complications of intrathecal chemotherapy in adults: single-institution experience in 109 consecutive patients. J. Oncol.2019, 4047617 (2019).
   PubMed Web of Science ®Google Scholar
• Gutin PH , LeviJA, WiernikPH, WalkerMD. Treatment of malignant meningeal disease with intrathecal thioTEPA: a phase II study. Cancer Treat. Rep.61(5), 885–887 (1977).
   PubMedGoogle Scholar
• Trump DL , GrossmanSA, ThompsonG, MurrayK, WharamM. Treatment of neoplastic meningitis with intraventricular thiotepa and methotrexate. Cancer Treat. Rep.66(7), 1549–1551 (1982).
   PubMedGoogle Scholar
• Giannone L , GrecoFA, HainsworthJD. Combination intraventricular chemotherapy for meningeal neoplasia. J. Clin. Oncol.4(1), 68–73 (1986).
   PubMed Web of Science ®Google Scholar
• Hitchins RN , BellDR, WoodsRL, LeviJA. A prospective randomized trial of single-agent versus combination chemotherapy in meningeal carcinomatosis. J. Clin. Oncol.5(10), 1655–1662 (1987).
   PubMed Web of Science ®Google Scholar
• Moseley RP , DaviesAG, RichardsonRBet al. Intrathecal administration of 131I radiolabelled monoclonal antibody as a treatment for neoplastic meningitis. Br. J. Cancer62(4), 637–642 (1990).
   PubMed Web of Science ®Google Scholar
• Meyers CA , ObbensEA, ScheibelRS, MoserRP. Neurotoxicity of intraventricularly administered alpha-interferon for leptomeningeal disease. Cancer68(1), 88–92 (1991).
   PubMed Web of Science ®Google Scholar
• Berg SL , BalisFM, ZimmSet al. Phase I/II trial and pharmacokinetics of intrathecal diaziquone in refractory meningeal malignancies. J. Clin. Oncol.10(1), 143–148 (1992).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , KhatibiS, KimJC, HowellSB, ChatelutE, KimS. Treatment of leptomeningeal metastasis with intraventricular administration of depot cytarabine (DTC 101). A phase I study. Arch. Neurol.50(3), 261–264 (1993).
   PubMed Web of Science ®Google Scholar
• Grossman SA , FinkelsteinDM, RuckdeschelJC, TrumpDL, MoynihanT, EttingerDS. Randomized prospective comparison of intraventricular methotrexate and thiotepa in patients with previously untreated neoplastic meningitis. Eastern Cooperative Oncology Group. J. Clin. Oncol.11(3), 561–569 (1993).
   PubMed Web of Science ®Google Scholar
• Rösener M , SchwuleraU, MenkeGet al. Tolerance and cerebrospinal fluid pharmacokinetics of intrathecally administered human natural interleukin-2: a phase I trial. Eur. Cytokine Netw.4(3), 189–195 (1993).
   PubMed Web of Science ®Google Scholar
• Bigner DD , BrownM, ColemanREet al. Phase I studies of treatment of malignant gliomas and neoplastic meningitis with 131I-radiolabeled monoclonal antibodies anti-tenascin 81C6 and anti-chondroitin proteoglycan sulfate Me1-14 F (ab’)2–a preliminary report. J. Neurooncol.24(1), 109–122 (1995).
   PubMed Web of Science ®Google Scholar
• Oldfield EH , RamZ, ChiangY, BlaeseRM. Intrathecal gene therapy for the treatment of leptomeningeal carcinomatosis. GTI 0108. A phase I/II study. Hum. Gene Ther.6(1), 55–85 (1995).
   PubMed Web of Science ®Google Scholar
• Kemshead JT , HopkinsKI, ChandlerCL. Treatment of diffuse leptomeningeal malignancy by intrathecal injection of 131I radioimmunoconjugates. Recent Results Cancer Res.141, 145–158 (1996).
   PubMedGoogle Scholar
• Laske DW , MuraszkoKM, OldfieldEHet al. Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery41(5), 1039–1051 (1997).
   PubMed Web of Science ®Google Scholar
• Bokstein F , LossosA, SiegalT. Leptomeningeal metastases from solid tumors: a comparison of two prospective series treated with and without intra-cerebrospinal fluid chemotherapy. Cancer82(9), 1756–1763 (1998).
   PubMed Web of Science ®Google Scholar
• Chamberlain MC , KormanikP. Carcinoma meningitis secondary to non-small cell lung cancer: combined modality therapy. Arch. Neurol.55(4), 506–512 (1998).
   PubMedGoogle Scholar
• Coakham HB , KemsheadJT. Treatment of neoplastic meningitis by targeted radiation using (131)I-radiolabelled monoclonal antibodies. Results of responses and long term follow-up in 40 patients. J. Neurooncol.38(2-3), 225–232 (1998).
   PubMed Web of Science ®Google Scholar
• Glantz MJ , JaeckleKA, ChamberlainMCet al. A randomized controlled trial comparing intrathecal sustained-release cytarabine (DepoCyt) to intrathecal methotrexate in patients with neoplastic meningitis from solid tumors. Clin. Cancer Res.5(11), 3394–3402 (1999).
   PubMed Web of Science ®Google Scholar
• Nakagawa H , YamadaM, MaedaN, IwatsukiK, HirayamaA, IkenakaK. Clinical trial of intrathecal administration of 5-fluoro-2′-deoxyuridine for treatment of meningeal dissemination of malignant tumors. J. Neurooncol.45(2), 175–183 (1999).
   PubMed Web of Science ®Google Scholar
• Kramer K , CheungNK, HummJLet al. Targeted radioimmunotherapy for leptomeningeal cancer using (131)I-3F8. Med. Pediatr. Oncol.35(6), 716–718 (2000).
   PubMedGoogle Scholar
• Jaeckle KA , PhuphanichS, BentMJet al. Intrathecal treatment of neoplastic meningitis due to breast cancer with a slow-release formulation of cytarabine. Br. J. Cancer84(2), 157–163 (2001).
   PubMed Web of Science ®Google Scholar
• Nakagawa H , MaedaN, TsuzukiTet al. Intracavitary chemotherapy with 5-fluoro-2′-deoxyuridine (FdUrd) in malignant brain tumors. Jpn. J. Clin. Oncol.31(6), 251–258 (2001).
   PubMed Web of Science ®Google Scholar
• Jaeckle KA , BatchelorT, O’DaySJet al. An open label trial of sustained-release cytarabine (DepoCyt) for the intrathecal treatment of solid tumor neoplastic meningitis. J. Neurooncol.57(3), 231–239 (2002).
   PubMed Web of Science ®Google Scholar
• Orlando L , CuriglianoG, ColleoniMet al. Intrathecal chemotherapy in carcinomatous meningitis from breast cancer. Anticancer Res.22(5), 3057–3059 (2002).
   PubMed Web of Science ®Google Scholar
• Blaney SM , HeidemanR, BergSet al. Phase I clinical trial of intrathecal topotecan in patients with neoplastic meningitis. J. Clin. Oncol.21(1), 143–147 (2003).
   PubMed Web of Science ®Google Scholar
• Cole BF , GlantzMJ, JaeckleKA, ChamberlainMC, MackowiakJI. Quality-of-life-adjusted survival comparison of sustained-release cytosine arabinoside versus intrathecal methotrexate for treatment of solid tumor neoplastic meningitis. Cancer97(12), 3053–3060 (2003).
   PubMed Web of Science ®Google Scholar
• Boogerd W , vanden Bent MJ, KoehlerPJet al. The relevance of intraventricular chemotherapy for leptomeningeal metastasis in breast cancer: a randomised study. Eur. J. Cancer40(18), 2726–2733 (2004).
   PubMed Web of Science ®Google Scholar
• Blaney SM , BalisFM, BergSet al. Intrathecal mafosfamide: a preclinical pharmacology and phase I trial. J. Clin. Oncol.23(7), 1555–1563 (2005).
   PubMed Web of Science ®Google Scholar
• Nakagawa H , MiyaharaE, SuzukiT, WadaK, TamuraM, FukushimaY. Continuous intrathecal administration of 5-fluoro-2′-deoxyuridine for the treatment of neoplastic meningitis. Neurosurgery57(2), 266–280 (2005).
   PubMed Web of Science ®Google Scholar
• Kramer K , HummJL, SouweidaneMMet al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J. Clin. Oncol.25(34), 5465–5470 (2007).
   PubMed Web of Science ®Google Scholar
• Nakagawa H , TamuraM, FukushimaY, MajimaS, YamadaK. Phase I study of intrathecal chemotherapy with NS-101 for leptomeningeal carcinomatosis in Japan. Gan To Kagaku Ryoho34(11), 1799–1805 (2007).
   PubMedGoogle Scholar
• Phuphanich S , MariaB, BraeckmanR, ChamberlainM. A pharmacokinetic study of intra-CSF administered encapsulated cytarabine (DepoCyt) for the treatment of neoplastic meningitis in patients with leukemia, lymphoma, or solid tumors as part of a phase III study. J. Neurooncol.81(2), 201–208 (2007).
   PubMed Web of Science ®Google Scholar
• Rudnicka H , NiwińskaA, MurawskaM. Breast cancer leptomeningeal metastasis–the role of multimodality treatment. J. Neurooncol.84(1), 57–62 (2007).
   PubMed Web of Science ®Google Scholar
• Bernardi RJ , BomgaarsL, FoxEet al. Phase I clinical trial of intrathecal gemcitabine in patients with neoplastic meningitis. Cancer Chemother. Pharmacol.62(2), 355–361 (2008).
   PubMed Web of Science ®Google Scholar
• Groves MD , GlantzMJ, ChamberlainMCet al. A multicenter phase II trial of intrathecal topotecan in patients with meningeal malignancies. Neuro. Oncol.10(2), 208–215 (2008).
   PubMed Web of Science ®Google Scholar
• Shinoura N , TabeiY, YamadaR, SaitoK, TakahashiM. Continuous intrathecal treatment with methotrexate via subcutaneous port: implication for leptomeningeal dissemination of malignant tumors. J. Neurooncol.87(3), 309–316 (2008).
   PubMed Web of Science ®Google Scholar
• Gauthier H , GuilhaumeMN, BidardFCet al. Survival of breast cancer patients with meningeal carcinomatosis. Ann. Oncol.21(11), 2183–2187 (2010).
   PubMed Web of Science ®Google Scholar
• Glantz MJ , HornAV, FisherR, ChamberlainMC. Route of intracerebrospinal fluid chemotherapy administration and efficacy of therapy in neoplastic meningitis. Cancer116(8), 1947–1955 (2010).
   PubMed Web of Science ®Google Scholar
• Gwak HS , LimHS, ShinSHet al. Ventriculolumbar perfusion chemotherapy for the treatment of leptomeningeal carcinomatosis: a phase I study with pharmacokinetic data. Am. J. Clin. Oncol.36(5), 491–499 (2013).
   PubMed Web of Science ®Google Scholar
• Gwak HS , JooJ, ShinSHet al. Ventriculolumbar perfusion chemotherapy with methotrexate for treating leptomeningeal carcinomatosis: a Phase II Study. Oncologist19(10), 1044–1045 (2014).
   PubMed Web of Science ®Google Scholar
• Pan Z , YangG, HeHet al. Concurrent radiotherapy and intrathecal methotrexate for treating leptomeningeal metastasis from solid tumors with adverse prognostic factors: a prospective and single-arm study. Int. J. Cancer139(8), 1864–1872 (2016).
   PubMed Web of Science ®Google Scholar
• Bonneau C , PaintaudG, TredanOet al. Phase I feasibility study for intrathecal administration of trastuzumab in patients with HER2 positive breast carcinomatous meningitis. Eur. J. Cancer95, 75–84 (2019).
   Web of Science ®Google Scholar
• Mrugala MM , KimB, SharmaAet al. Phase II study of systemic high-dose methotrexate and intrathecal liposomal cytarabine for treatment of leptomeningeal carcinomatosis from breast cancer. Clin. Breast Cancer19(5), 311–316 (2019).
   PubMed Web of Science ®Google Scholar
• Le Rhun E , WalletJ, MailliezAet al. Intrathecal liposomal cytarabine plus systemic therapy versus systemic chemotherapy alone for newly diagnosed leptomeningeal metastasis from breast cancer. Neuro Oncol.22(4), 524–538 (2020).
   PubMed Web of Science ®Google Scholar
• Malani R , FleisherM, KumthekarPet al. Cerebrospinal fluid circulating tumor cells as a quantifiable measurement of leptomeningeal metastases in patients with HER2 positive cancer. J. Neurooncol.148(3), 599–606 (2020).
   PubMed Web of Science ®Google Scholar
• Fan C , ZhaoQ, LiLet al. Efficacy and safety of intrathecal pemetrexed combined with dexamethasone for treating tyrosine kinase inhibitor-failed leptomeningeal metastases from EGFR-mutant NSCLC – a prospective, open-label, single-arm phase 1/2 clinical trial (unique identifier: ChiCTR1800016615). J. Thorac. Oncol.16(8), 1359–1368 (2021).
   PubMed Web of Science ®Google Scholar
• Lu ZQ , CaiJ, WangXet al. Osimertinib combined with bevacizumab for leptomeningeal metastasis from EGFR-mutation non-small cell lung cancer: a phase II single-arm prospective clinical trial. Thorac. Cancer12(2), 172–180 (2021).
   PubMed Web of Science ®Google Scholar
• Brastianos PK , StricklandMR, LeeEQet al. Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis. Nat. Commun.12(1), 5954 (2021).
   PubMed Web of Science ®Google Scholar
• Pan ZY , SongYY, JiangTC, YangX, YangGZ. Clinical trials on intrathecal pemetrexed treated leptomeningeal metastases from solid tumors. Zhonghua Zhong Liu Za Zhi44(1), 112–119 (2022).
   PubMedGoogle Scholar
• Kumthekar PU , AvramMJ, LassmanABet al. A phase I/II study of intrathecal trastuzumab in HER-2 positive cancer with leptomeningeal metastases: safety, efficacy, and cerebrospinal fluid pharmacokinetics. Neuro Oncol.25(3), 557–565 (2023).
   PubMed Web of Science ®Google Scholar
• Brastianos PK , LeeEQ, CohenJVet al. Single-arm, open-label phase 2 trial of pembrolizumab in patients with leptomeningeal carcinomatosis. Nat. Med.26(8), 1280–1284 (2020).
   PubMed Web of Science ®Google Scholar
• Intraventricular Administration of Rhenium-186 NanoLiposome for Leptomeningeal Metastases (ReSPECT-LM) . https://clinicaltrials.gov/study/NCT05034497 (Accessed 23August2023).
   Google Scholar
• Yang JT , WijetungaNA, PentsovaEet al. Randomized phase II trial of proton craniospinal irradiation versus photon involved-field radiotherapy for patients with solid tumor leptomeningeal metastasis. J. Clin. Oncol.40(33), 3858–3867 (2022).
   PubMed Web of Science ®Google Scholar
• A Study of Deferoxamine (DFO) in People With Leptomeningeal Metastasis . https://classic.clinicaltrials.gov/ct2/show/NCT05184816 (Accessed 23August2023).
   Google Scholar
• Chi Y , RemsikJ, KiseliovasVet al. Cancer cells deploy lipocalin-2 to collect limiting iron in leptomeningeal metastasis. Science369(6501), 276–282 (2020).
   PubMed Web of Science ®Google Scholar